Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
15.66
-1.25 (-7.39%)
Sep 15, 2026, 1:06 PM EDT - Market open
Sutro Biopharma Employees
Sutro Biopharma had 128 employees as of June 30, 2026. The number of employees decreased by 116 or -47.54% compared to the same quarter last year.
Employees
128
Change
-116
Growth
-47.54%
Revenue / Employee
$357,047
Profits / Employee
-$1,411,219
Market Cap
259.66M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 128 | -116 | -47.54% |
| Mar 31, 2026 | 133 | -136 | -50.56% |
| Dec 31, 2025 | 137 | -173 | -55.81% |
| Sep 30, 2025 | 178 | -128 | -41.83% |
| Jun 30, 2025 | 244 | -60 | -19.74% |
| Mar 31, 2025 | 269 | -31 | -10.33% |
| Dec 31, 2024 | 310 | 8 | 2.65% |
| Sep 30, 2024 | 306 | 8 | 2.68% |
| Jun 30, 2024 | 304 | 7 | 2.36% |
| Mar 31, 2024 | 300 | 8 | 2.74% |
| Dec 31, 2023 | 302 | 24 | 8.63% |
| Sep 30, 2023 | 298 | 39 | 15.06% |
| Jun 30, 2023 | 297 | 55 | 22.73% |
| Mar 31, 2023 | 292 | 58 | 24.79% |
| Dec 31, 2022 | 278 | 54 | 24.11% |
| Sep 30, 2022 | 259 | 41 | 18.81% |
| Jun 30, 2022 | 242 | 38 | 18.63% |
| Mar 31, 2022 | 234 | 39 | 20.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Fate Therapeutics | 161 |
| Lyell Immunopharma | 161 |
| AC Immune | 122 |
| Immuneering | 57 |
| Pyxis Oncology | 56 |
| ALX Oncology Holdings | 48 |
| Camp4 Therapeutics | 48 |
STRO News
- 4 weeks ago - Sutro Biopharma reports Q2 EPS ($2.33), consensus ($2.27) - TheFly
- 4 weeks ago - H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data - TheFly
- 4 weeks ago - Sutro Biopharma price target lowered to $34 from $41 at Citizens - TheFly
- 4 weeks ago - Sutro Biopharma Slides: Corporate presentation - Filings
- 4 weeks ago - Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study - GlobeNewsWire
- 4 weeks ago - Sutro Biopharma Earnings release: Q2 2026 - Filings
- 4 weeks ago - Sutro Biopharma Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Sutro Biopharma initiated with a Buy at Stifel - TheFly